TY - JOUR
T1 - Racial disparities in the screening and treatment of diabetic retinopathy
AU - Coney, Joseph M.
AU - Scott, Adrienne W.
N1 - Funding Information:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publisher Copyright:
© 2022 National Medical Association
PY - 2022/4
Y1 - 2022/4
N2 - Diabetic retinopathy is a progressive disease and primary retinal vascular complication of diabetes mellitus, the third leading cause of blindness in the United States. Racial and ethnic minorities are more likely to suffer from diabetic retinopathy and diabetic macular edema, and typically undergo less screening. Lack of screening is due to a variety of factors, such as patient, provider, and institutional barriers. Due to the disparity in screening, minorities often present with more advanced stages of diabetic eye disease. As the minority population increases, the burden of treatment for these patients will also increase. It is imperative to understand the barriers and social determinants of health limiting visual outcomes in minority populations. Diabetic retinopathy and its complications are often preventable if detected and treated early. Advances in screening technology and intravitreal anti-VEGF injections have changed the landscape in preventing vision loss in diabetic patients.
AB - Diabetic retinopathy is a progressive disease and primary retinal vascular complication of diabetes mellitus, the third leading cause of blindness in the United States. Racial and ethnic minorities are more likely to suffer from diabetic retinopathy and diabetic macular edema, and typically undergo less screening. Lack of screening is due to a variety of factors, such as patient, provider, and institutional barriers. Due to the disparity in screening, minorities often present with more advanced stages of diabetic eye disease. As the minority population increases, the burden of treatment for these patients will also increase. It is imperative to understand the barriers and social determinants of health limiting visual outcomes in minority populations. Diabetic retinopathy and its complications are often preventable if detected and treated early. Advances in screening technology and intravitreal anti-VEGF injections have changed the landscape in preventing vision loss in diabetic patients.
KW - Barriers
KW - Diabetic retinopathy
KW - Diabetic retinopathy screening
KW - Disparities in eye care
KW - Minority health screening
UR - http://www.scopus.com/inward/record.url?scp=85123740541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123740541&partnerID=8YFLogxK
U2 - 10.1016/j.jnma.2021.12.011
DO - 10.1016/j.jnma.2021.12.011
M3 - Article
C2 - 35105457
AN - SCOPUS:85123740541
SN - 0027-9684
VL - 114
SP - 171
EP - 181
JO - Journal of the National Medical Association
JF - Journal of the National Medical Association
IS - 2
ER -